

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT7849163

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
REDX PHARMA PLC	03/16/2023
REDX ONCOLOGY LTD	03/16/2023
RECEIVING PARTY DATA	
Name:	LOXO ONCOLOGY, INC.
Street Address:	LILLY CORPORATE CENTER
Internal Address:	PATENT DIVISION
City:	INDIANAPOLIS
State/Country:	INDIANA
Postal Code:	46285
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	16063542
Application Number:	16109162
Application Number:	16113661
Application Number:	15930657
Application Number:	17122103
Application Number:	17525350
CORRESPONDENCE DATA	
Fax Number:	(317)276-3861
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patents@lilly.com
Correspondent Name:	ELI LILLY AND COMPANY
Address Line 1:	P. O. BOX 6288
Address Line 2:	PATENT DIVISION
Address Line 4:	INDIANAPOLIS, INDIANA 46206-6288
ATTORNEY DOCKET NUMBER:	X22365_US FAMILY
NAME OF SUBMITTER:	PATRICIA A FOOR
SIGNATURE:	/Patricia A Foor/

DATE SIGNED:	03/16/2023
Total Attachments: 9 source=X22365 Confirmatory Assignment#page1.tif source=X22365 Confirmatory Assignment#page2.tif source=X22365 Confirmatory Assignment#page3.tif source=X22365 Confirmatory Assignment#page4.tif source=X22365 Confirmatory Assignment#page5.tif source=X22365 Confirmatory Assignment#page6.tif source=X22365 Confirmatory Assignment#page7.tif source=X22365 Confirmatory Assignment#page8.tif source=X22365 Confirmatory Assignment#page9.tif	

CONFIRMATORY ASSIGNMENT

This Confirmatory Assignment Agreement ("Assignment") is made and entered into by and between Redx Pharma plc ("Redx Pharma"), a corporation formed under the laws of the United Kingdom and having a principal place of business at Block 33, Mereside, Alderley Park, Macclesfield SK10 4TG, United Kingdom and Redx Oncology Ltd. ("Redx Oncology"), a corporation formed under the laws of the United Kingdom and having a principal place of business at Block 33, Mereside, Alderley Park, Macclesfield, SK10 4TG, United Kingdom (Redx Pharma and Redx Oncology collectively referred to herein as "Assignors"), on the one hand, and Loxo Oncology, Inc. ("Assignee"), an Indiana, USA, corporation, having its principal place of business at Lilly Corporate Center, Indianapolis, IN 46285 and a correspondence address of c/o Eli Lilly and Company, P.O. Box 6288, Indianapolis, IN 46206-6288, and which is a wholly-owned subsidiary of Eli Lilly and Company, an Indiana, U.S., corporation having its principal place of business at Lilly Corporate Center, Indianapolis, IN 46285, on the other hand.

WHEREAS Nicolas E.S. Guisot ("Guisot") was at all relevant times an employee of the Assignors, having the job title BTK Project Leader at the relevant time;

WHEREAS, Guisot is an inventor of the patents and patent applications listed in Schedule A ("Schedule A Patents") and is an inventor of the inventions and improvements which are the subject of the Schedule A Patents (collectively, the "Inventions");

WHEREAS, pursuant to section 39(1) of the Patents Act 1977 in force at all relevant times in the United Kingdom, the Inventions, and any right, title and interest of Guisot in those Inventions, are taken to belong to the Assignor (the "Assigned Rights", (as defined below) as confirmed in the confirmatory assignment dated 19 July 2018;

WHEREAS, on July 29, 2017, Assignors and Assignee entered into an Assignment ("2017 Assignment") pursuant to which Assignors assigned to Assignee all of their right, title, and interest throughout the world in and to the Assigned Rights (as defined below);

WHEREAS, Assignee now wishes to confirm it has secured from Assignors their entire right, title, and interest throughout the world in and to the Assigned Rights (as defined below).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by all parties, the parties confirm as follows:

1. For purposes of this Confirmatory Assignment, the following terms have the following meanings:

(a) The "Patents" means (i) the Schedule A Patents; (ii) any and all patents, patent applications, utility models and certificates of inventions filed or issued worldwide from which any of the Schedule A Patents claim priority; (iii) any and all patents, patent applications, utility models, and certificates of invention filed or issued worldwide claiming priority to any of the patents, patent applications, utility models, and certificates of invention in (i)-(ii) including all continuations, continuations-in-part, and divisionals; (iv) all reissues, reexaminations, extensions (including patent term extensions and patent term adjustments), and supplementary protection certificates of any of the patents, patent applications, utility models, and certificates of invention in (i)-(iii) and any patents resulting from any post-grant proceedings involving any of the patents, patent applications, utility models, and certificates of invention in (i)-(iii) including any *inter partes* review, any post-grant review, and any oppositions; and (v) any other patents, patent applications, utility models, and certificates of invention filed or issued worldwide claiming any inventions disclosed in the Schedule A Patents.

(b) The "Assigned Rights" means (i) the Patents; (ii) the inventions disclosed in the Patents; (iii) the right to file, prosecute, maintain, and defend the Patents, in its own name wherever so permitted by law or in the name of Assignors wherever necessary; (iv) the right to claim priority to any of the Patents pursuant to the Paris Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and (v) the right to sue and collect damages and any other relief for any past, present, and future infringement of the Patents.

2. Each Assignor hereby confirms it assigned to Assignee all of its right, title, and interest throughout the world in and to the Assigned Rights. Each Assignor hereby confirms it has sold, assigned, transferred, and set over, unto Assignee, its lawful successors and assigns, all of Assignor's right, title, and interest throughout the world in and to the Assigned Rights. For the further avoidance of doubt, each Assignor hereby confirms it assigned to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, that each Assignor has or may have against any party for any past, present, or future infringement of the Patents.

3. Each Assignor shall, when requested by Assignee and at no cost to each Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and all other papers necessary and proper to carry out the intent and purpose of the Assignment and this Confirmatory Assignment, (ii) execute all papers necessary in connection with the Assigned Rights and execute any separate assignment in connection with any of the Assigned Rights as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions including as may be necessary to record the assignment of the Patents in the records of all relevant intellectual property registries. Each Assignor hereby appoints Assignee to be its attorney in its name and on its behalf to execute documents, use each Assignor's name and do all things which are necessary or desirable

for Assignee to obtain for itself or its nominee the full benefit of the Assignment and this Confirmatory Assignment in relation to the Assigned Rights. This power of attorney is irrevocable and is given by way of security to secure the performance of each Assignor's obligations under this clause and the proprietary interest of Assignee in the Assigned Rights and so long as such obligations of each Assignor remain undischarged, or Assignee has such interest, the power may not be revoked by either Assignor, save with the consent of Assignee.

5. This Confirmatory Assignment is binding upon and inures to the benefit of the successors and permitted assigns of the parties.

6. This Confirmatory Assignment and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the laws of England and Wales.

7. Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with this Confirmatory Assignment or its subject matter or formation.

IN WITNESS WHEREOF, the parties, through their authorized officers or individually, have executed this Assignment as of the dates below.

Redx Pharma plc

By

Name:

Title: CHIEF OPERATING OFFICER

Date:

Redx Oncology Ltd.

By

Name:

Title: CHIEF OPERATING OFFICER

Date:

Loxo Oncology, Inc.

By

Name: Tina M. Tyson

Title: Associate Vice President -
Assistant General Patent Counsel

Date:

SCHEDULE A PATENTS

Application No.	Publication No. (if applicable)	Patent No.	Jurisdiction
GB1308975.0	N/A		Great Britain
GB1309085.7	N/A		Great Britain
PCT/GB2014/051542	WO 2014/188173		International
GB1311951.6	GB 2515785		Great Britain
GB1312901.0	GB 2516303		Great Britain
GB1404987.8	N/A		Great Britain
PCT/GB2015/050819	WO 2015/140566		International
GB1410430.1	N/A		Great Britain
PCT/GB2015/051719	WO 2015/189620		International
15/317,323	US 2017/0129897	9975897	United States
15/977470	US 2019-0119281-A1	10538524	United States
AU2015273217	AU2015273217	2015273217	Australia
CA2951504	CA2951504		Canada
CN2015800431556	CN106661035	ZL201580043155.6	China
EP20150729910.8	EP3154978	3154978	Europe
19166894.6			Europe
15729910.8	3154978		France
15729910.8	3154978		Germany (Federal Republic of)
17110299.8	1236526A	HK 1236526	Hong Kong
IN201617042162	201617042162		India
502019000042867	3154978	3154978	Italy
JP2016572754	2017-519754	6721521	Japan
15729910.8	2732897	3154978	Spain
15729910.8	3154978	3154978	Great Britain
GB1516445.2	N/A		Great Britain
GB1522246.6	N/A		Great Britain
GB1613947.9	N/A		Great Britain
PCT/GB2016/052897	WO2017/046604		International
2016322063			Australia
BR112018005189-6	2491		Brazil
2998796			Canada
2018-00706	2018-00706		Chile

201680066694.6	108431007	ZL201680066694.6	China
202210413117.7	114685516		China
201890730	201890730		Eurasian Patent Convention
16770328.9	3350184	3350184	European Patent
22189973.5	4116303		European Patent
16770328.9		3350184	France
16770328.9		3350184	Germany (Federal Republic of)
19101139.9			Hong Kong
201837012921	201837012921		India
258154			Israel
16770328.9		3350184	Italy
2018-514423	2018-527384		Japan
10-2018-7010521			Korea, Republic of (KR)
MX/a/2018/003351	MX/a/2018/003351		Mexico
PV/42175			Morocco
740757			New Zealand
PCT/GB2016/052897	WO 2017/046604		Patent Cooperation Treaty
1-2018-500587			Philippines
112018021550			Singapore
2018/01958			South Africa
16770328.9		3350184	Spain
1801001607			Thailand
a 2018 02838			Ukraine
16770328.9		3350184	Great Britain
15/762367		10611766	United States of America
16/109223	US-2018-0362533- A1	10399989	United States of America
16/113533	US-2018-0362537- A1	10399990	United States of America
GB1522245.8	N/A		Great Britain
GB1613945.3	N/A		Great Britain
PCT/GB2016/053968	WO2017/103611		International
AL-P-2020-802	3390395	3390395	Albania

180358		11771	Algeria
AP/P/2018/010875		AP 5669	ARIPO
AP/P/2021/013044			ARIPO
AP/P/2021/013577			ARIPO
201891268	201891268 A1	035132	Armenia
2016373530		2016373530	Australia
2021201811		2021201811	Australia
2021225162			Australia
2021225161			Australia
16816363.2	3390395	3390395	Austria
16816363.2	3390395	3390395	Belgium
E 03657	3390395	BA/EP3390395	Bosnia and Herzegovina
AP/P/2018/010875		AP 5669	Botswana
AP/P/2021/013044			Botswana
AP/P/2021/013577			Botswana
BR122021004031-1			Brazil
BR112018012341-2	BR112018012341-2		Brazil
BR122022003876-0			Brazil
16816363.2	3390395	3390395	Bulgaria
3008488			Canada
2018-01591	2018-01591	62.962	Chile
201680073031.7	108473481	ZL201680073031.7	China
202111022492.0	CN113636978X		China
202111022488.4	CN113603645X		China
202210312076.2	114621146		China
202210311970.8	CN114573510		China
202210312064.X	CN114605327		China
202210312050.8	114591242		China
202210310724.0	CN114716381		China
202210311995.8	CN114634447X		China
NC2018/0006164	839	36448	Colombia
2018-0367			Costa Rica
P 20201835	3390395	3390395	Croatia
CY20201101090	3390395	3390395	Cyprus (Republic of)
16816363.2	3390395	3390395	Czechia
16816363.2	3390395	3390395	Denmark
986/2018			Egypt
986/2018 D1			Egypt
986/2018 D2			Egypt
16816363.2	3390395	3390395	Estonia
201891268	201891268 A1	035132	Eurasian Patent

			Convention
16816363.2	3390395	3390395	European Patent
20194724.9	3782994		European Patent
16816363.2	3390395	3390395	Finland
16816363.2	3390395	3390395	France
16816363.2	3390395	602016043800.3	Germany (Federal Republic of)
AP/P/2018/010875		AP 5669	Ghana
AP/P/2021/013044			Ghana
AP/P/2021/013577			Ghana
16816363.2	3390395	3390395	Greece
18114157.0	1263254A	HK1263254	Hong Kong
42022048375.4	40059756A		Hong Kong
42022048366.3	40059212A		Hong Kong
16816363.2	3390395	3390395	Hungary
16816363.2	3390395	3390395	Iceland
201817024795	201817024795	414946	India
PID201804580			Indonesia
16816363.2	3390395	3390395	Ireland (Republic of)
281067	281067	281067	Israel
259923	259923	259923	Israel
276283	276283	276283	Israel
285976			Israel
502020000110253	3390395	3390395	Italy
2018-532035	2018-538307	6731483	Japan
2022-092275	2022-120013		Japan
2020-116636	2020-172535	7086140	Japan
201891268	201891268 A1	035132	Kazakhstan
AP/P/2018/010875		AP 5669	Kenya
AP/P/2021/013044			Kenya
AP/P/2021/013577			Kenya
10-2021-7003683			Korea, Republic of (KR)
10-2021-7003683			Korea, Republic of (KR)
10-2018-7020225		10-2215792	Korea, Republic of (KR)
16816363.2	3390395	3390395	Latvia

5328/2018			Libya
16816363.2	3390395	3390395	Liechtenstein
16816363.2	3390395	3390395	Lithuania
16816363.2	3390395	3390395	Luxembourg
PI 2018000902			Malaysia
PI2022003990			Malaysia
PI2022003988			Malaysia
PI2022003989			Malaysia
16816363.2	3390395	3390395	Malta
MX/a/2018/007267		380907	Mexico
MX/a/2021/003478	52	394193	Mexico
16816363.2	3390395	3390395	Moldova
16816363.2	3390395	3390395	Monaco
P 2020/242	3390395	03926	Montenegro
PV/42871		42871	Morocco
49809			Morocco
AP/P/2018/010875		AP 5669	Namibia
AP/P/2021/013044			Namibia
AP/P/2021/013577			Namibia
16816363.2	3390395	3390395	Netherlands
743553	1718	743553	New Zealand
779445			New Zealand
779446			New Zealand
			North Macedonia
MK/P/2020/772	3390395	P 911148	
16816363.2	3390395	3390395	Norway
92262	374	92262-01	Panama
92262-02			Panama
92262-03	390		Panama
1143.2018	1143.2018		Peru
1581-2021	PE 20220507		Peru
1592-2021	PE 20220502		Peru
1-2018-501268	WO/2017/103611		Philippines
16816363.2	3390395	3390395	Poland
16816363.2	3390395	3390395	Portugal
16816363.2	3390395	3390395	Romania
			Russian Federation
201891268	201891268 A1	035132	
16816363.2	3390395	3390395	Serbia
10202012498T	N/A		Singapore
11201805044W		11201805044W	Singapore
			Slovak Republic
16816363.2	3390395	3390395	
16816363.2	3390395	3390395	Slovenia
2021/00544			South Africa

2018/04137			South Africa
2021/07471			South Africa
2021/07472			South Africa
2020/03176			South Africa
16816363.2	3390395	3390395	Spain
16816363.2	3390395	3390395	Sweden
16816363.2	3390395	3390395	Switzerland
1801003503	1801003503A		Thailand
TN2018/0213		26113	Tunisia
16816363.2	3390395	TR 2020 15752 T4	Turkey
201807294		122258	Ukraine
2021 05628			Ukraine
2021 05627			Ukraine
2020 03795			Ukraine
16816363.2	3390395	3390395	Great Britain
17/122103	US-2021-0093611-A1	11471441	United States of America
15/930657	US-2020-0276162-A1	10918622	United States of America
16/063542	US-2019-0135762-A1	10695323	United States of America
16/109162	US-2018-0362512-A1	10342780	United States of America
16/113661	US-2019-0000806-A1	10464905	United States of America
17/525,350	US-2022-0062239-A1		United States of America
1-2018-02651	61544	32417	Vietnam
1-2021-05630			Vietnam
1-2021-05629			Vietnam